

Special Issue

Drug Resistance and Novel Targets for Cancer Therapy—Second Edition

Message from the Guest Editors

Drug resistance is a complex phenomenon resulting from one or more mechanisms which render cells resistant to anticancer drugs. Molecular hallmarks of cancer and therapeutics against drug resistance mechanisms are the leading targets for cancer treatment. Molecular targeted therapy is gaining attraction due to its specificity to cancer while sparing normal cells. Despite this, drug resistance still represents a major obstacle that limits sustained clinical benefits not only to targeted cancer therapies, but also conventional chemotherapy. In this context, we are proposing a new Special Issue encompassing these two major molecular pathways involved in cancer treatment such as the determinations of new cancer related molecular targets, development of drugs that block them and drugs that aims resistance to treatment. We invite innovative research papers and review articles discussing new molecular targets or anticancer drugs. We encourage articles related, but not restricted to Apoptosis Induction, Proliferative Signaling, Angiogenesis, Metastasis, Immune Checkpoint, Tumor Vaccine Related Targets, Chimeric Antigen Receptor T-Cell or their possible drug resistance mechanisms.

Guest Editors

Dr. Bruno Kaufmann Robbs

Instituto de Saúde de Nova Friburgo, Universidade Federal Fluminense, Nova Friburgo, Brazil

Dr. Fernando de Carvalho da Silva

Departamento de Química Orgânica, Instituto de Química, Universidade Federal Fluminense, Niterói 24020-141, RJ, Brazil

Deadline for manuscript submissions

closed (31 May 2025)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/196365

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).